This site is intended for U.S. residents only. For Novartis Worldwide, Click here

Mailing List


	Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only.

Study Description

Screening

Study Centers

Contact/Consent

Eczema/Dermatitis

Also called atopic eczema, this is a chronic, hereditary, condition often triggered by environmental factors. The skin itches intensely and is dry and inflamed, with episodes of redness, weeping, crusting, cracking, and scaling. Atopic dermatitis most often affects infants and young children, but it can continue into adulthood or even first occur later in life. The condition fluctuates, with exacerbations or flares. The disease is associated with other so-called atopic disorders, such as hay fever and asthma.

Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial.

How to use this system:

The purpose of this system is to help connect interested study participants with clinical research centers. The following is a brief outline explaining the main steps involved in using this system. Please note that every step in this process is optional.

1. Select a clinical trial that you feel best suits your (or the      participant's) health condition.
2. Answer the screening questions to see if you (or the      participant) meet the preliminary qualifications for the study.      The answers to these questions are not retained by this      system.
3. Select a study center to contact for additional information      about the clinical trial.
4. Set up an account and agree to the terms of use for this      system.
5. Submit your information to the study center you selected.
6. The study center may contact you and may ask more      questions about your (or the participant's) eligibility for the      study. The study center may invite you (and the participant if      applicable) to travel to the study center for additional screening      tests. Novartis cannot guarantee that you will be contacted by      the study center.
7. If you are eligible to participate in the study, then you will be      required to sign an informed consent before enrolling in the      study. An informed consent is provided to you to help you      understand the clinical trial, the nature of the medical treatment      (if any), procedures and known risks involved, before you agree      to participate in the study.

For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy.

Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.

Pediatric Eczema Elective Registry (PEER Program)

Novartis Pharmaceuticals Corporation is sponsoring a Pediatric Eczema Elective Registry (PEER) to monitor the long-term safety of topical calcineurin inhibitors. This scientific observational registry is designed to collect information from the parents of approximately 5000 children across the USA between the ages of 2 years and 17 years (at enrollment) who have used and may continue to use Elidel® for the treatment of eczema. For more information on this program, please visit www.childrenseczemaregistry.com or call 1-877-711-7337.
Trial phase: Phase 4
Participation Duration: Up to 10 years from the time of enrollment.
Protocol Number: CASM981CUS2311

	Site Map \| Contact Us \| Clinical Trial Search \| Mailing List \| Clinical Trial FAQs
	Participation FAQs \| Clinical Trials Glossary \| About Informed Consent
	Novartis Medical and Clinical Research

Clinical Trial Search

Eczema/Dermatitis